IPM Take
This is where precision oncology stops being a metastatic-only conversation. If adjuvant targeted therapy is moving into resected lung cancer, then early-stage systems need routine biomarker testing, rapid pathology turnaround, referral discipline and reimbursement rules that do not wait until the cancer has already returned.
Executive Summary
Phase III ELEVATE data published in The New England Journal of Medicine showed that ensartinib improved disease-free survival after complete resection in ALK-positive stage IB–IIIB non-small cell lung cancer. In stage II–IIIB disease, the 24-month disease-free survival rate was 86.4% with ensartinib versus 53.5% with placebo, with a hazard ratio of 0.20. In the full stage IB–IIIB cohort, the 24-month disease-free survival rate was 87.3% versus 57.2%. Overall survival data were immature. Grade 3 or higher adverse events occurred in 35.8% of ensartinib-treated patients versus 18.2% in the placebo group.
Why it matters
- Patients / advocates: Recurrence prevention is not abstract. For patients who have already gone through surgery, reducing recurrence risk can mean changing the future.
- Clinicians: The adjuvant treatment conversation is becoming more molecular, not only more anatomical.
- Diagnostics / pathology: ALK testing must move earlier in the pathway, not appear only when metastatic disease is diagnosed.
- Hospitals / providers: Early-stage lung cancer care now requires stronger coordination between surgery, oncology, pathology and molecular testing.
For years, biomarker testing in lung cancer was treated as a metastatic-disease problem. That era is closing.
The ELEVATE trial puts the pressure where it belongs: on the early-stage pathway. Patients with completely resected ALK-positive NSCLC were randomised to receive ensartinib or placebo after surgery and any planned adjuvant chemotherapy. The result was not subtle. At 24 months, disease-free survival in stage II–IIIB disease was 86.4% with ensartinib compared with 53.5% with placebo. Across the full stage IB–IIIB cohort, the gap remained large: 87.3% versus 57.2%.
That is the kind of signal that changes the clinical mood.
But it also exposes a familiar policy weakness. Targeted adjuvant treatment only works as a system intervention if the system knows who has the target. That means ALK testing cannot be delayed, rationed or treated as optional after surgery. It has to be built into the front end of the lung-cancer pathway.
This will not be equally easy everywhere. Some centres already run reflex testing. Others still depend on clinician request, tissue availability, payer permission or local lab capacity. In early-stage disease, the timing is tighter. Treatment decisions arrive quickly after surgery. If the molecular result is late, the pathway becomes late.
The ELEVATE data are also not a blank cheque. Overall survival remains immature, and toxicity is real. Grade 3 or higher adverse events were reported more often with ensartinib than with placebo. So the next policy question is not simply whether the drug works. It is whether the right patients can be identified, counselled and monitored without turning early-stage precision oncology into another elite-centre privilege.
This is the new test for lung cancer readiness: not whether a country has heard of ALK, but whether it can find ALK-positive disease before the recurrence clock starts winning.
